Skip to content

Opus Genetics IRD Accounts Receivable

Accounts Receivable at other companies

AbbVie logo
AbbVieABBV
$12.48B0.0%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$3.26M+345%
Opko Health logo
Opko HealthOPK
$79.64M-17.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$5.73B+3.1%
Regenxbio logo
RegenxbioRGNX
$10.04M-44.8%
Prime Medicine logo
Prime MedicinePRME
$0-100%

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$307.14M+442%
Enterprise value$248.38M
P/S25.6×+21.5×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×
Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opus Genetics's accounts receivable?
Opus Genetics (IRD) reported accounts receivable of $1.73M in Q1 2026.
How has Opus Genetics's accounts receivable changed year-over-year?
Opus Genetics's accounts receivable decreased by 43.8% year-over-year, from $3.08M to $1.73M.
What does accounts receivable mean?
Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.